A common promoter hypomethylation signature in invasive breast, liver and prostate cancer cell lines reveals novel targets involved in cancer invasiveness

Oncotarget

Volumn 6, Issue 32, 2015, Pages 33253-33268

  Cheishvili, David ^a   Stefanska, Barbara ^a,e   Yi, Cao ^a   Li, Chen Chen ^a   Yu, Patricia ^a   Arakelian, Ani ^a   Tanvir, Imrana ^b   Khan, Haseeb Ahmed ^b   Rabbani, Shafaat ^a   Szyf, Moshe ^a,c,d  

^a MCGILL UNIVERSITY   (Canada)

^b FATIMA MEMORIAL HOSPITAL   (Pakistan)

^c MCGILL UNIVERSITY   (Canada)

^d CANADIAN INSTITUTE FOR ADVANCED RESEARCH   (Canada)

^e PURDUE UNIVERSITY   (United States)

Author keywords

DNA methylation; Drug targets; Epigenetics; Hypomethylation; Inasiveness

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA; TRANSCRIPTOME;

5' UNTRANSLATED REGION; ADOLESCENT; ADULT; AGED; ARTICLE; BREAST CANCER; C11ORF68 GENE; CARCINOGENESIS; CELL INVASION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; FEMALE; G0S2 GENE; GENE; GENE ACTIVATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIVER CANCER; MALE; PROMOTER REGION; PROSTATE CANCER; SHISA2 GENE; TMEM156 GENE; UPREGULATION; BREAST TUMOR; GENETICS; HEP-G2 CELL LINE; LIVER TUMOR; MCF-7 CELL LINE; MICROARRAY ANALYSIS; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE; TUMOR INVASION;

BREAST NEOPLASMS; CELL LINE, TUMOR; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MALE; MCF-7 CELLS; MICROARRAY ANALYSIS; NEOPLASM INVASIVENESS; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; TRANSCRIPTOME;

EID: 84946031804     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5291     Document Type: Article

References (49)

1. GraffJ.R, et al. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res. 1995; 55:5195-9.
2. Herman J.G, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 1995; 55:4525-30.
3. Baylin S.B., Jones P.A. A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer. 2011; 11:726-34.
4. Pakneshan P, et al. Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis. J Biol Chem. 2004; 279:31735-44.
5. Stefanska B, et al. Definition of the landscape of promoter DNA hypomethylation in liver cancer. Cancer Res. 2011; 71:5891-903.
6. Shukeir N, et al. Alteration of the Methylation Status of Tumor-Promoting Genes Decreases Prostate Cancer Cell Invasiveness and Tumorigenesis In vitro and In vivo. Cancer Res. 2006; 66:9202-10.
7. Fang F, et al. Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med. 2011; 3:75ra25.
8. Zhu Q.S, et al. Vimentin is a novel AKT1 target mediating motility and invasion. Oncogene. 2011; 30:457-70.
9. Gil-Henn H, et al. Arg/Abl2 promotes invasion and attenuates proliferation of breast cancer in vivo. Oncogene. 2013; 32:2622-30.
10. Suzuki M, et al. Bikunin target genes in ovarian cancer cells identified by microarray analysis. J Biol Chem. 2003; 278:14640-6.
11. Guo Y, et al. Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion. J Biol Chem. 2002; 277:41571-9.
12. Drabsch Y., ten Dijke P. TGF-beta signalling and its role in cancer progression and metastasis. Cancer Metastasis Rev. 2012; 31:553-68.
13. Matuo Y, et al. Production and significance of TGF-beta in AT-3 metastatic cell line established from the Dunning rat prostatic adenocarcinoma. Biochem Biophys Res Commun. 1990; 166:840-7.
14. Welch D.R., Fabra A., Nakajima M. Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci U S A. 1990; 87:7678-82.
15. Vervoort S.J, et al. SOX4 mediates TGF-beta-induced expression of mesenchymal markers during mammary cell epithelial to mesenchymal transition. PLoS One. 2013; 8:e53238.
16. Yoshida K, et al. Transforming growth factor-beta transiently induces vimentin expression and invasive capacity in a canine mammary gland tumor cell line. Res Vet Sci. 2013; 94:539-41.
17. Katsuno Y., Lamouille S., Derynck R. TGF-beta signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol. 2013; 25:76-84.
18. Eccles S.A, et al. Significance of the c-erbB family of receptor tyrosine kinases in metastatic cancer and their potential as targets for immunotherapy. Invasion Metastasis. 1994; 14:337-48.
19. Borg A, et al. HER2/neu amplification and comedo type breast carcinoma. Lancet. 1989; 1:1268-9.
20. Seshadri R, et al. The significance of oncogene amplification in primary breast cancer. Int J Cancer. 1989; 43:270-2.
21. Orphanos G., Kountourakis P. Targeting the HER2 receptor in metastatic breast cancer. Hematol Oncol Stem Cell Ther. 2012; 5:127-37.
22. Andre F., Zielinski C.C. Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncol. 2012; 23:vi46-51.
23. Dogan B.E., Turnbull L.W. Imaging of triple-negative breast cancer. Ann Oncol. 2012; 23:vi23-9.
24. Verma S, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012; 367:1783-91.
25. Fleischer T, et al. Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis. Genome Biol. 2014; 15:435.
26. Varambally S, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell. 2005; 8:393-406.
27. Schuetz C.S, et al. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer Res. 2006; 66:5278-86.
28. Kuner R, et al. The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer. J Mol Med (Berl). 2013; 91:237-48.
29. Welch C, et al. Identification of a protein, G0S2, that lacks Bcl-2 homology domains and interacts with and antagonizes Bcl-2. Cancer Res. 2009; 69:6782-9.
30. Zandbergen F, et al. The G0/G1 switch gene 2 is a novel PPAR target gene. Biochem J. 2005; 392:313-24.
31. Kobayashi S, et al. Expression profiling of PBMC-based diagnostic gene markers isolated from vasculitis patients. DNA Res. 2008; 15:253-65.
32. Yang X, et al. The G(0)/G(1) switch gene 2 regulates adipose lipolysis through association with adipose triglyceride lipase. Cell Metab. 2010; 11:194-205.
33. Nagano T, et al. Shisa2 promotes the maturation of somitic precursors and transition to the segmental fate in Xenopus embryos. Development. 2006; 133:4643-54.
34. Bediaga N.G, et al. DNA methylation epigenotypes in breast cancer molecular subtypes. Breast Cancer Res. 2010; 12:R77.
35. Feng W, et al. Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res. 2007; 9:R57.
36. Bertolo C, et al. Differences and molecular immunohistochemical parameters in the subtypes of infiltrating ductal breast cancer. Am J Clin Pathol. 2008; 130:414-24.
37. Stefanska B, et al. Genome-wide study of hypomethylated and induced genes in patients with liver cancer unravels novel anticancer targets. Clin Cancer Res. 2014; 20:3118-32.
38. Kusakabe M, et al. Identification of G0S2 as a gene frequently methylated in squamous lung cancer by combination of in silico and experimental approaches. Int J Cancer. 2010; 126:1895-902.
39. Yamada T, et al. G0S2 inhibits the proliferation of K562 cells by interacting with nucleolin in the cytosol. Leuk Res. 2014; 38:210-7.
40. Kenji Tamura M.F., Satake Hirofumi, Anchi Takashi, Kamei Maiko, Fukuhara Hideo, Shimamoto Tsutomu, Ashida Shingo, Karashima Takashi, Yamasaki Ichiro, Nishikawa Hiroshi, Kamada Masayuki, Yasuda Masaharu, Inoue Keiji, Shuin Taro. Identification and functional analysis of SHISA2 overexpressed in prostate cancer. Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research. Chicago, IL, Philadelphia (PA): 2012;.
41. Hsu Y.T, et al. Promoter hypomethylation of EpCAMregulated bone morphogenetic protein gene family in recurrent endometrial cancer. Clin Cancer Res. 2013; 19:6272-85.
42. Knowles B.B., Howe C.C., Aden D.P. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science. 1980; 209:497-9.
43. Soule H.D, et al. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst. 1973; 51:1409-16.
44. Horoszewicz J.S, et al. LNCaP model of human prostatic carcinoma. Cancer Res. 1983; 43:1809-18.
45. Fogh J., Fogh J.M., Orfeo T. One hundred and twentyseven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst. 1977; 59:221-6.
46. Cailleau R, et al. Breast tumor cell lines from pleural effusions. J Natl Cancer Inst. 1974; 53:661-74.
47. Kaighn M.E, et al. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol. 1979; 17:16-23.
48. Crudo A, et al. Prenatal synthetic glucocorticoid treatment changes DNA methylation States in male organ systems: multigenerational effects. Endocrinology. 2012; 153:3269-83.
49. Tost J., Gut I.G. DNA methylation analysis by pyrosequencing. Nat Protoc. 2007; 2:2265-75.